二、《关于董事会换届暨选举第三届董事会独立董事的议案》 经过对公司第三届董事会独立董事候选人的背景、工作经历的了解，我们认 为公司第三届董事会独立董事候选人未持有公司股份，与公司控股股东、实际控 制人及其他董事候选人、监事候选人之间不存在关联关系，不存在《公司法》规 定的不得担任公司董事的情形，未受到中国证券监督管理委员会的行政处罚或交 易所惩戒，不属于相关法律法规、部门规章、规范性文件等规定的不得担任公司 独立董事的情形。 无锡祥生医疗科技股份有限公司独立董事 关于第二届董事会第十九次会议相关议案的独立意见 无锡祥生医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 9 日召 开第二届董事会第十九次会议（以下简称"会议"）。根据《中华人民共和国公司 法》等法律、法规及《无锡祥生医疗科技股份有限公司章程》的相关规定，我们 作为公司的独立董事，在认真审阅有关文件资料后，对公司第二届董事会第十九 次会议相关议案，发表如下独立意见： 一、《关于董事会换届暨选举第三届董事会非独立董事的议案》 经过对公司第三届董事会非独立董事候选人的背景、工作经历的了解，我们 认为第三届董事会非独立董事候选人不存在《公司 ...

无锡祥生医疗科技股份有限公司董事会现提名李寿喜为无锡祥生医疗科技 股份有限公司第三届董事会独立董事候选人,并已充分了解被提名人职业专长、 教育背景、工作经历、兼任职务等情况。被提名人已书面同意出任无锡祥生医疗 科技股份有限公司第三届董事会独立董事候选人。提名人认为,被提名人具备独 立董事任职资格,与无锡祥生医疗科技股份有限公司之间不存在任何影响其独立 性的关系,具体声明如下: 独立董事提名人声明 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、行政法规、规 章及其他规范性文件,具有五年以上法律、经济、财务、管理或者其他履行独立 董事职责所必需的工作经验,并已根据相关规定取得独立董事资格证书。 (二)《公务员法》关于公务员兼任职务的规定; (三)中央纪委、中央组织部《关于规范中管干部辞去公职或者退(离)休 后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定; (四)中央纪委、教育部、监察部《关于加强高等学校反腐倡廉建设的意见》 关于高校领导班子成员兼任职务的规定; (五)中国保监会《保险公司独立董事管理暂行办法》的规定; (六)其他法律、行政法规和部门规章规定的情形。 三、被提名人具备独立性,不 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2023-015 无锡祥生医疗科技股份有限公司 关于召开 2022 年度医疗设备专场集体业绩说明会 暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 无锡祥生医疗科技股份有限公司（以下简称"公司"）已于2023年4月19日在 上海证券交易所网站（www.sse.com.cn）披露公司《2023年年度报告》和《2023 年第一季度报告》，为便于广大投资者更全面深入地了解公司2023年度以及2023 年第一季度经营成果、财务状况，公司参与了由上海证券交易所主办的2022年度 医疗设备专场集体业绩说明会，计划于2023年6月16日14:00-15:00召开2022年度 医疗设备专场集体业绩说明会暨2023年第一季度业绩说明会，就投资者关心的问 题进行交流。 一、 说明会类型 本次说明会以视频结合网络互动方式召开，公司将针对 2022 年度及 2023 年第一季度经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信 息 ...

Financial Performance - The company's operating revenue for 2022 was ¥380,843,344.13, a decrease of 4.27% compared to ¥397,811,875.09 in 2021[19]. - The net profit attributable to shareholders for 2022 was ¥105,842,831.46, down 5.89% from ¥112,472,408.71 in the previous year[19]. - The net profit after deducting non-recurring gains and losses increased by 25.87% to ¥98,440,015.40 in 2022 from ¥78,207,777.43 in 2021[19]. - The net cash flow from operating activities for 2022 was ¥63,741,276.37, representing a significant increase of 59.51% compared to ¥39,960,965.16 in 2021[19]. - The total assets at the end of 2022 were ¥1,513,926,604.17, an increase of 8.29% from ¥1,398,069,571.61 at the end of 2021[19]. - The net assets attributable to shareholders increased by 5.45% to ¥1,313,508,192.90 at the end of 2022 from ¥1,245,581,541.50 at the end of 2021[19]. - The weighted average return on equity decreased to 8.30%, down from 9.27% in the previous year[21]. - The gross profit margin improved to 59.28%, up by 2.99 percentage points from the previous year[98]. - The company achieved a net loss of ¥392.78 million for Xiangsheng Technology, with total assets of ¥681.20 million[118]. Research and Development - The company increased its R&D investment by 7.74% year-on-year, reaching CNY 77.88 million, which accounted for a record high of 20.45% of total operating revenue[30]. - The company registered 31 new patents in 2022, including 20 invention patents, and submitted 75 new intellectual property applications[30]. - The company has a comprehensive R&D model with centers in China and the U.S., focusing on core technologies from material research to system design[40]. - The company has made significant breakthroughs in specialized ultrasound technologies, particularly in breast and vascular access imaging, as well as in artificial intelligence and remote diagnosis[66]. - The company is focusing on breakthroughs in high-end imaging technology and probe technology to enhance its competitive edge in the ultrasound sector[57]. - The company has developed a range of proprietary technologies, including 1-3 composite material transducer technology and high-performance single crystal material technology, to improve probe efficiency and sensitivity[71]. - The company has established a proprietary algorithm for real-time ultrasound image transmission, ensuring high-quality imaging even under low bandwidth conditions, positioning itself as a leader in the domestic market[68]. Market Strategy and Expansion - Future strategies include market expansion and potential mergers and acquisitions to enhance product offerings and market presence[18]. - The company has expanded its product coverage significantly, with products now reaching over 30% of tertiary hospitals and being sold in more than 100 countries and regions[36][37]. - The company aims to focus on high-end ultrasound technology, portable ultrasound devices, and ultrasound artificial intelligence as part of its strategic development goals[121]. - The company plans to enhance brand building and market penetration through regional activities and new media promotion strategies[123]. - Market expansion efforts led to a 30% increase in international sales, with significant growth in the European market[134]. Corporate Governance - The company maintains a governance structure that ensures independence and coordination among the board of directors, supervisory board, and management[130]. - The company has a robust governance framework that adheres to the regulations set forth by the China Securities Regulatory Commission[130]. - The company has not faced any major issues regarding independence or operational autonomy from its controlling shareholder[130]. - The company has established a compensation and assessment committee responsible for formulating remuneration plans for senior management personnel[140]. - The company held four shareholder meetings during the reporting period, all of which complied with relevant laws and regulations, and the resolutions were legally valid[129]. Social Responsibility and Environmental Initiatives - The company actively participates in social responsibility initiatives, contributing a total of 21.46 million CNY, including 0.88 million CNY in cash donations and 20.58 million CNY in material donations[179]. - The company emphasizes environmental protection, having implemented measures to prevent pollution and ensure compliance with local environmental standards, with no administrative penalties received for environmental issues[173]. - The company has integrated green energy-saving design concepts into its product development, promoting low-power consumption products across its entire product line[177]. - The company has implemented strict waste management practices, including recycling and proper disposal of hazardous materials, to minimize environmental impact[175]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 7 RMB per 10 shares, totaling approximately 78.49 million RMB, which represents 74.15% of the net profit attributable to shareholders for 2022[5]. - The total share capital as of December 31, 2022, was 112,124,537 shares, which will be the basis for the dividend distribution[156]. - The cash dividend distribution plan is subject to approval at the shareholders' meeting[156]. - The company has a clear and defined dividend policy that complies with its articles of association and shareholder resolutions[157]. Risks and Challenges - The company has detailed risk factors that may affect its operations in the management discussion and analysis section of the report[4]. - The company faces risks related to product development failures and potential technology leaks, which could impact its competitive position in the market[86]. - The company is exposed to financial risks, including potential increases in bad debts and inventory write-downs due to market fluctuations[91]. - The company faced risks related to new product registration, particularly in the context of evolving regulatory environments[90].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 165,154,528.52, representing a year-on-year increase of 64.55%[5] - The net profit attributable to shareholders was CNY 52,513,874.14, reflecting a growth of 111.31% compared to the same period last year[6] - Basic earnings per share (EPS) stood at CNY 0.47, up by 113.64% from the previous year[6] - Total operating revenue for Q1 2023 reached RMB 165,154,528.52, a 64.6% increase from RMB 100,367,467.51 in Q1 2022[22] - Net profit for Q1 2023 was RMB 52,513,874.14, representing a 111.1% increase compared to RMB 24,852,007.66 in Q1 2022[23] - The company reported a total profit of RMB 59,674,856.98 for Q1 2023, an increase from RMB 29,011,776.30 in Q1 2022[23] Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 3,297,962.45, an increase of 133.51% year-on-year[6] - Cash flow from operating activities generated a net amount of RMB 3,297,962.45, a significant improvement from a net outflow of RMB 9,842,847.19 in Q1 2022[26] - Cash and cash equivalents at the end of Q1 2023 totaled RMB 476,375,439.25, down from RMB 734,839,296.15 at the end of Q1 2022[27] - Investment activities generated a net cash inflow of RMB 35,595,811.20 in Q1 2023, compared to RMB 307,397,052.00 in Q1 2022[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,591,043,073.39, a 5.09% increase from the end of the previous year[6] - The company's total equity as of March 31, 2023, was CNY 1,367,393,741.24, up from CNY 1,313,508,192.90, marking an increase of approximately 4.1%[19] - The total current liabilities rose to CNY 212,505,799.94, compared to CNY 188,470,568.81 at the end of 2022, reflecting an increase of about 12.7%[18] - The total liabilities increased to CNY 223,649,332.15 from CNY 200,418,411.27, reflecting an increase of about 11.6%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,354[13] - The top shareholder, Wuxi Xiangsheng Investment Co., Ltd., holds 40.46% of the shares, totaling 45,360,000 shares[13] Research and Development - Research and development (R&D) expenses totaled CNY 19,931,113.52, accounting for 12.07% of operating revenue, a decrease of 6.83 percentage points[6] - Research and development expenses for Q1 2023 were RMB 19,931,113.52, slightly up from RMB 18,967,543.27 in Q1 2022[22] Other Financial Metrics - The company experienced a 902.82% increase in financial expenses, mainly due to foreign exchange losses[11] - The company reported a foreign exchange loss of RMB 5,789,980.73 in Q1 2023, compared to a loss of RMB 1,209,622.83 in Q1 2022[27] - Accounts receivable increased by 128.36%, primarily due to the growth in domestic and international sales revenue[10] - Accounts receivable increased significantly to CNY 213,565,566.53 from CNY 93,521,760.48, representing a growth of approximately 128%[17] - The company's inventory decreased to CNY 161,833,169.93 from CNY 196,957,143.80, a decline of approximately 17.8%[17] - The non-current assets totaled CNY 178,752,164.59, slightly up from CNY 175,100,762.63, indicating a growth of about 1.5%[18] - The company reported a significant increase in other non-current assets to CNY 8,411,230.63 from CNY 5,500,476.00, representing a growth of approximately 52.1%[18] - The company's retained earnings rose to CNY 294,240,893.63 from CNY 241,727,019.49, an increase of approximately 21.7%[19]

无锡祥生医疗科技股份有限公司 投资者关系活动记录表 证券代码：688358 证券简称：祥生医疗 编号：2022-003 无锡祥生医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------------|-------|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

无锡祥生医疗科技股份有限公司 投资者关系活动记录表 证券代码：688358 证券简称：祥生医疗 编号：2022-004 无锡祥生医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-------|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥125,824,572.92, representing a year-on-year increase of 23.49%[5] - Net profit attributable to shareholders for the same period was ¥49,864,043.16, up 62.99% year-on-year[5] - The net profit after deducting non-recurring gains and losses reached ¥49,233,278.27, reflecting a 68.22% increase compared to the previous year[5] - Basic and diluted earnings per share were both ¥0.45, an increase of 66.67% compared to the same period last year[6] - The net profit attributable to shareholders for the year-to-date period was ¥125,599,972.62, up 61.49% year-on-year[5] - Net profit for the third quarter of 2022 was ¥125,599,972.62, compared to ¥77,775,013.19 in the same quarter of 2021, reflecting an increase of approximately 61.5%[22] - Basic and diluted earnings per share for the third quarter of 2022 were both ¥1.12, up from ¥0.69 in the same quarter of 2021, marking a growth of about 62.3%[23] Cash Flow - The cash flow generated from operating activities was ¥16,415,556.55, showing a significant increase of 869.81% year-on-year[6] - Cash inflow from operating activities for the first three quarters of 2022 totaled ¥368,785,244.45, compared to ¥308,432,725.95 in 2021, representing an increase of approximately 19.6%[24] - The net cash flow from operating activities was $28,769,350.89, a significant increase from $3,554,235.75 in the previous year, reflecting a strong operational performance[25] - The total cash outflow from operating activities was $340,015,893.56, an increase from $304,878,490.20 year-over-year, reflecting higher operational costs[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,519,940,604.82, an increase of 8.72% from the end of the previous year[6] - As of September 30, 2022, the total assets of Wuxi Xiangsheng Medical Technology Co., Ltd. amounted to CNY 1,519,940,604.82, an increase from CNY 1,398,069,571.61 at the end of 2021, reflecting a growth of approximately 8.7%[16] - The total liabilities as of the end of the third quarter of 2022 were ¥183,050,920.88, an increase from ¥152,488,030.11 at the end of the previous year, reflecting a growth of approximately 20.1%[21] - Total current liabilities increased to CNY 175,167,467.17 from CNY 139,726,642.35, which is an increase of about 25.4%[17] - The company reported a total non-current asset value of CNY 158,521,522.35, up from CNY 127,756,854.19, reflecting a growth of approximately 24.1%[17] Research and Development - Research and development expenses totaled ¥23,618,053.04, accounting for 18.77% of operating revenue, which is an increase of 0.09 percentage points year-on-year[6] - Research and development expenses for the third quarter of 2022 amounted to ¥62,010,190.82, up from ¥49,822,013.70 in the same quarter of 2021, indicating a growth of about 24.4%[21] Shareholder Information - The company reported a total of 6,437 common shareholders at the end of the reporting period[12] - The total equity attributable to shareholders reached ¥1,336,889,683.94, compared to ¥1,245,581,541.50 in the previous year, indicating an increase of about 7.3%[21] Dividend and Investment Activities - The company paid $40,000,000.00 in dividends during the quarter, a decrease from $64,000,000.00 in the same period last year, reflecting a change in dividend policy[25] - The total cash inflow from investment activities was $1,621,226,645.21, compared to $2,220,758,253.10 in the same quarter last year, indicating a decrease in investment returns[25] - The net cash flow from investment activities was $251,719,545.52, down from $528,654,789.97 year-over-year, suggesting a decline in investment profitability[25] - The cash outflow for investment activities was $1,369,507,099.69, compared to $1,692,103,463.13 in the previous year, indicating a reduction in capital expenditures[25] Tax and Deferred Income - The company reported a tax expense of ¥14,185,566.51 for the third quarter of 2022, compared to ¥6,421,552.97 in the same quarter of 2021, which is an increase of approximately 120.5%[22] - Deferred income as of the end of the third quarter of 2022 was ¥2,108,248.15, down from ¥3,542,468.62 in the previous year, indicating a decrease of about 40.5%[21] Market and Future Outlook - The company has not disclosed any new product launches or technological advancements in the provided reports[15] - There are no indications of market expansion or mergers and acquisitions mentioned in the current financial reports[15] - The report does not provide specific future outlook or performance guidance for the upcoming quarters[15]

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with a total revenue of RMB 500 million, representing a 25% year-over-year growth[1]. - The company's operating revenue for the first half of 2022 was ¥228,340,546.82, representing a 22.28% increase compared to ¥186,736,993.01 in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2022 was ¥75,735,929.46, a significant increase of 60.52% from ¥47,182,329.52 in the previous year[18]. - The net cash flow from operating activities reached ¥12,353,794.34, marking a 117.24% increase compared to ¥5,686,663.49 in the same period last year[18]. - The gross margin for the first half of 2022 improved to 45%, up from 40% in the same period last year[1]. - The net profit after deducting non-recurring gains and losses was ¥74,457,578.14, reflecting a 65.10% increase from ¥45,097,897.38 in the same period last year[18]. - The total comprehensive income for the period was CNY 75,706,438.12, an increase of 60% from CNY 47,284,484.73 in the prior year[148]. User Growth and Market Outlook - User data indicates that the active user base has grown to 1.2 million, an increase of 15% compared to the previous year[1]. - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 20% to 30%[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region by the end of 2023[99]. - The company is positioned to capitalize on the growing demand for portable ultrasound devices, particularly in community hospitals and primary healthcare settings[26]. Research and Development - The company is investing in R&D, with a budget increase of 30% for new technology development in medical imaging equipment[1]. - The R&D expenditure accounted for 16.81% of operating revenue, an increase of 0.32 percentage points from 16.49% in the previous year[19]. - The company has established a comprehensive R&D system with centers in the US and China, covering various interdisciplinary technologies including electronics, acoustics, and signal processing[36]. - The company is focusing on technological advancements and product development in the high-end medical equipment sector[24]. - The company has developed core technologies in the field of whole-body ultrasound, including harmonic imaging and multi-mode composite imaging, which enhance image resolution and reduce noise[41]. Strategic Initiatives - Market expansion plans include entering two new international markets by Q4 2022, aiming for a 10% market share in each[1]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of completing at least one acquisition by the end of 2022[1]. - The company is actively expanding its overseas marketing network and enhancing local channel construction to support steady growth in international business[20]. - The company is pursuing patent applications for various technologies, including low-power mode recognition algorithms for handheld ultrasound devices[42]. Financial Management and Compliance - The management emphasizes the importance of maintaining compliance with regulatory standards to ensure continued market access[1]. - The company has committed to continuous innovation in ultrasound technology, with a focus on enhancing product reliability, stability, and imaging quality[30]. - The company will ensure that investors' legal rights are effectively protected and will comply with judicial documents regarding compensation[108]. - The company has established a mechanism to ensure compliance with the Shanghai Stock Exchange's mandatory regulations[98]. Challenges and Risks - The company has identified potential risks related to supply chain disruptions, which could impact future performance[1]. - The company faces challenges including low industry concentration and significant competition from imported high-end medical devices[29]. - The company is facing macroeconomic risks, including trade friction and global pandemic uncertainties, which could impact sales and supply chains[75]. Shareholder Information - The company distributed a cash dividend of RMB 0.5 per share, totaling RMB 40 million, based on a total share capital of 80 million shares, and increased the total share capital to 112 million shares after a capital reserve conversion[124]. - The largest shareholder, Wuxi Xiangsheng Investment Co., Ltd., holds 32.4 million shares, accounting for 40.50% of the total shares[127]. - The company has not experienced any changes in its share capital structure during the reporting period[122]. Environmental and Social Responsibility - The company primarily produces and sells ultrasound medical imaging equipment, which is not classified as a heavily polluting product[94]. - The company has committed to not transferring or entrusting the management of its shares for 36 months following its listing on the Shanghai Stock Exchange[97]. - A commitment to sustainability initiatives was reiterated, with plans to reduce carbon emissions by 15% over the next three years[99].

Financial Performance - The company's operating revenue for 2021 was CNY 397,811,875.09, representing a year-over-year increase of 19.43% compared to CNY 333,092,749.95 in 2020[23]. - The net profit attributable to shareholders of the listed company was CNY 112,472,408.71, which is a 12.88% increase from CNY 99,636,077.03 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was CNY 78,207,777.43, showing a decrease of 13.95% from CNY 90,882,587.82 in 2020[23]. - The net cash flow from operating activities decreased by 51.53% to CNY 39,960,965.16 from CNY 82,448,047.94 in the previous year[23]. - As of the end of 2021, the total assets amounted to CNY 1,398,069,571.61, reflecting a 3.59% increase from CNY 1,349,604,046.26 at the end of 2020[23]. - The net assets attributable to shareholders of the listed company increased by 4.42% to CNY 1,245,581,541.50 from CNY 1,192,905,095.43 at the end of 2020[23]. - The company's comprehensive gross profit margin decreased slightly to 56.29% compared to the previous year[104]. - The company achieved operating revenue of RMB 397.81 million, a year-on-year increase of 19.43% due to increased overseas sales[104]. - Operating costs rose to RMB 173.88 million, reflecting a year-on-year increase of 26.02%, primarily due to exchange rate fluctuations[104]. Research and Development - Research and development expenses totaled RMB 72,286,400, accounting for 18.17% of operating revenue, with a year-on-year increase of 29.93%[33]. - The company added 30 new patent authorizations during the reporting period, including 9 invention patents[33]. - The company is investing in research and development of AI technologies to improve diagnostic capabilities and operational efficiency[14]. - The company achieved a total of 316 patent authorizations by the end of the reporting period, including 83 invention patents, with 7 being valid international patents[80]. - The company has developed several proprietary technologies, including high-performance single crystal materials and wideband phased array technology, to improve probe sensitivity and bandwidth[78]. - The company has established a national postdoctoral workstation and engineering technology research center to foster talent development[92]. - The company is focusing on low-power hardware system optimizations to improve battery life and storage time in portable ultrasound devices[72]. - The company has developed a noise suppression algorithm that ensures maximum signal-to-noise ratio under various blood flow speed detection conditions[71]. Corporate Governance - The company has confirmed that all board members were present at the board meeting, ensuring governance compliance[5]. - The company has established a governance structure that ensures independence and coordination among shareholders, the board of directors, and management[137]. - The company held two shareholder meetings during the reporting period, adhering to legal and regulatory requirements[139]. - The total compensation for the chairman of the board is reported at 364,000 RMB for the period[141]. - The company has established specialized committees, including an audit committee and a remuneration committee, to enhance governance[156]. - The company has not faced any penalties from securities regulatory authorities in the past three years[153]. - The company has a clear organizational structure with a focus on governance, including a board of directors and supervisory board, ensuring compliance with relevant regulations[187]. Market Strategy and Expansion - The company aims to enhance its market presence through strategic partnerships and potential acquisitions in the healthcare technology sector[14]. - The company is actively pursuing strategic partnerships and potential acquisitions to bolster its competitive position in the market[145]. - The company plans to enhance its domestic market investment while pursuing a dual marketing strategy to expand its sales channels[130]. - The company is exploring opportunities in international markets to diversify its revenue streams and reduce dependency on domestic sales[145]. - The company is focused on expanding its product line in ultrasound technology, including portable and AI-assisted systems[91]. - The company has established a nationwide sales network covering over 30 provinces and regions in China, positioning itself to leverage the significant growth potential in the domestic ultrasound market[62]. Risk Management - The company has outlined potential risks in its operations, which are detailed in the management discussion and analysis section of the report[4]. - The company faces risks related to the registration of new products, which may delay market entry and impact business plans[94]. - The company is heavily reliant on ultrasound products and related technical services, making it vulnerable to market demand fluctuations[95]. - The company has a risk of research and development investments not generating timely economic benefits due to the lengthy product development cycle[93]. - The company is actively expanding its marketing network and product offerings in various clinical fields to mitigate market development risks[95]. Social Responsibility - The company actively participated in various charitable activities, donating over 1 million CNY worth of ultrasound equipment to support flood relief efforts in Henan[185]. - The company has engaged in social responsibility initiatives, including donations of medical supplies during the COVID-19 pandemic[185]. - The company’s board emphasizes the importance of ESG (Environmental, Social, and Governance) practices and has been involved in various community support activities[184]. Employee and Talent Management - The company has a structured compensation policy that includes fixed salaries, performance bonuses, and stock incentives for different employee categories[162]. - The company emphasizes talent acquisition and retention through various incentive mechanisms, including stock options and performance bonuses, to achieve strategic goals[131]. - The company achieved an 18% overall personnel growth, with nearly a 20% increase in R&D staff, and successfully recruited 5 PhDs to enhance its R&D capabilities[36]. - The average salary of R&D personnel increased to ¥22.42 million from ¥21.54 million in the previous year[88]. Future Outlook - Future guidance indicates a continued growth trajectory with an emphasis on innovation and market expansion strategies[14]. - The company plans to invest 50 million RMB in R&D for innovative technologies over the next fiscal year[149]. - The company provided a future outlook, projecting a revenue growth of 10% for the next quarter, aiming for 1.65 billion RMB[149]. - The company plans to strengthen its talent development through partnerships with educational institutions and the establishment of a postdoctoral work station[133].